-
Mashup Score: 0Quality of Life Preservation - 1 month(s) ago
Dr. Motzer shares his viewpoint on quality-of-life preservation observed with different regimens for nccRCC patients.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 4Risk/Benefits of Managing AEs with Combination Therapy - 1 month(s) ago
Dr. Motzer discusses the risk/benefits considerations that guide decisions around continuing combination therapy with dose adjustments or stopping one agent when moderate AEs like diarrhea or liver enzyme elevations emerge in nccRCC patients on IO plus TKI regimens.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1Initial Impression of Case - 2 month(s) ago
Dr. Motzer provides his perspective on the notable aspects of this nccRCC case and how it compares to typical cases.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1
Clinical trials are shedding light into best treatment approaches for non–clear cell renal cell carcinoma, including immunotherapy plus tyrosine kinase inhibitor combinations, as discussed in Case-Based Roundtable events.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
WATCH: @motzermd shares his viewpoint on quality-of-life preservation observed with different regimens for #nccRCC patients. #KCSM https://t.co/EhhsIYuICs